Seroatlas · Human Serome Atlas

SLC2A2

Solute carrier family 2, facilitated glucose transporter member 2

Also known as: GLUT-2, GLUT2, GTR2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P11168
Gene
SLC2A2
Ensembl
ENSG00000163581
Chromosome
3
Canonical length
524 aa
Protein class
Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters
Subcellular location
Plasma membrane,Mid piece,Principal piece

OverviewNCBI Gene

This gene encodes an integral plasma membrane glycoprotein of the liver, islet beta cells, intestine, and kidney epithelium. The encoded protein mediates facilitated bidirectional glucose transport. Because of its low affinity for glucose, it has been suggested as a glucose sensor. Mutations in this gene are associated with susceptibility to diseases, including Fanconi-Bickel syndrome and noninsulin-dependent diabetes mellitus (NIDDM). Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jul 2013]

Canonical amino-acid sequenceUniProt

524 residues, UniProt reviewed canonical sequence.

>P11168|SLC2A2
     1  MTEDKVTGTL VFTVITAVLG SFQFGYDIGV INAPQQVIIS HYRHVLGVPL DDRKAINNYV
    61  INSTDELPTI SYSMNPKPTP WAEEETVAAA QLITMLWSLS VSSFAVGGMT ASFFGGWLGD
   121  TLGRIKAMLV ANILSLVGAL LMGFSKLGPS HILIIAGRSI SGLYCGLISG LVPMYIGEIA
   181  PTALRGALGT FHQLAIVTGI LISQIIGLEF ILGNYDLWHI LLGLSGVRAI LQSLLLFFCP
   241  ESPRYLYIKL DEEVKAKQSL KRLRGYDDVT KDINEMRKER EEASSEQKVS IIQLFTNSSY
   301  RQPILVALML HVAQQFSGIN GIFYYSTSIF QTAGISKPVY ATIGVGAVNM VFTAVSVFLV
   361  EKAGRRSLFL IGMSGMFVCA IFMSVGLVLL NKFSWMSYVS MIAIFLFVSF FEIGPGPIPW
   421  FMVAEFFSQG PRPAALAIAA FSNWTCNFIV ALCFQYIADF CGPYVFFLFA GVLLAFTLFT
   481  FFKVPETKGK SFEEIAAEFQ KKSGSAHRPK AAVEMKFLGA TETV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC2A2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
12
Mean surface accessibility (rSASA)
0.25
Highest tissue expression
782 nTPM

Expression across tissuesHPA

Tissue

  • liver: 782 nTPM
  • duodenum: 62 nTPM
  • small intestine: 45 nTPM
  • kidney: 29 nTPM
  • gallbladder: 4.9 nTPM
  • pancreas: 2.2 nTPM

Single-cell type

  • hepatocytes: 750 nCPM
  • enterocytes: 226 nCPM
  • cholangiocytes: 141 nCPM
  • proximal tubule cells: 57 nCPM
  • epicardial cells: 9.1 nCPM
  • enteric transient amplifying cells: 8.8 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • white matter: 4.9 nTPM
  • medulla oblongata: 2.1 nTPM
  • basal ganglia: 2 nTPM
  • pons: 1.8 nTPM
  • cerebral cortex: 1.3 nTPM
  • midbrain: 1.3 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC2A2.

Disease | AllUniProt

Conditions SLC2A2 is implicated in, by any mechanism.

Disease | GeneticClinVar

58 pathogenic / likely-pathogenic of 383 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.92
gnomAD pLI
0
gnomAD missense Z
0.94
DepMap mean gene effect
0.05
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC2A2 as an antibody target. Whether an autoantibody or antibody against SLC2A2 could matter depends on whether native SLC2A2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC2A2 is annotated at the cell surface, where native SLC2A2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC2A2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC2A2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...